GeneDx CEO's TIME100 Nod Signals Tipping Point for Genomic Medicine

GAITHERSBURG, MD – February 11, 2026 – In a significant acknowledgment of the growing influence of genomics on global health, Katherine Stueland, President and CEO of GeneDx, has been named to the 2026 TIME100 Health list. The annual recognition by TIME, which honors the 100 most influential individuals in health, places Stueland among the world’s foremost leaders shaping the future of medicine.

The announcement, strategically timed during Rare Disease Month, highlights a pivotal moment for the rare disease community and the broader healthcare landscape. It serves as a powerful validation of the shift toward using genomic data to diagnose complex conditions, a field where Stueland has positioned GeneDx (Nasdaq: WGS) as a definitive leader. Under her guidance, the company has championed the cause of shortening the painful “diagnostic odyssey”—a journey that, on average, forces families to wait more than five years for an accurate diagnosis.

“Katherine’s inclusion in the TIME100 Health list reflects the growing importance of genomics in modern medicine and the meaningful progress GeneDx has made for patients with rare and genetic conditions,” said Jason Ryan, Chairman of the GeneDx Board of Directors. Ryan emphasized that Stueland is not only advancing a bold mission but has also built a “profitable and rapidly growing business that has elevated GeneDx as a pivotal player in the healthcare ecosystem.”

From Diagnostic Odyssey to Proactive Health

For millions of families worldwide, the path to understanding a loved one's rare condition is fraught with uncertainty, misdiagnoses, and years of unanswered questions. GeneDx aims to replace this reactive cycle with a proactive model built on genomic insight. By scaling access to high-quality exome and genome sequencing, the company provides clinicians with the tools to find answers faster and more accurately than ever before.

At the heart of this capability is GeneDx Infinity™, the world’s largest and most comprehensive genomic dataset focused on rare diseases. This massive repository of data, combined with advanced AI, allows the company to identify disease-causing genetic variants with unparalleled precision. This technological advantage is turning the tide, moving rare disease from the periphery of medicine toward the center of global health conversations.

“Being named to the TIME100 Health is an incredible honor, but the real recognition is for the rare disease community, who rallies behind each new patient and family who is facing a diagnosis and the journey to find a treatment or cure,” said Stueland. “This moment reflects a broader shift in healthcare, as genomic data, clinical insight, and policy begin to align in powerful new ways. We now can move from a system that reacts to illness to one that anticipates it.”

The New Frontier: Genomic Newborn Screening

Perhaps the most transformative application of GeneDx's work is its pioneering role in genomic newborn screening (gNBS). The company is the sequencing and interpretation partner for the nation’s most ambitious public-private initiatives, which are providing critical data on the feasibility of integrating genomics into standard newborn care.

These landmark programs include:

• The GUARDIAN study in New York City: A groundbreaking effort focused on using rapid genome sequencing for critically ill newborns, which has already identified a screen positive rate of 3.7%, enabling life-altering interventions within days of birth.
• BEACONS: A multi-state, NIH-funded program evaluating the logistics and ethics of offering genomic sequencing as a public health tool for both sick and healthy newborns.
• Florida’s Sunshine Genetics Program: The first state-funded initiative to implement gNBS as part of standard screening for newborns in academic hospitals, signaling a major step toward state-level adoption.

Together, these studies are demonstrating that the timeline for diagnosing rare diseases can be compressed from years to days. This shift promises to move healthcare from a reactive posture to one of proactive, population-scale health, ensuring every child has access to answers from the very beginning.

A Turning Point in Clinical Practice and Regulation

GeneDx's momentum is further bolstered by two recent, industry-defining milestones. The company’s exome and genome tests were granted Breakthrough Device Designation by the U.S. Food and Drug Administration (FDA). This program is reserved for technologies that have the potential to provide more effective diagnosis for life-threatening or irreversibly debilitating diseases, signaling the FDA’s recognition of the tests' significant clinical impact and helping to expedite their path to broader patient access.

In parallel, the American Academy of Pediatrics (AAP) issued updated clinical guidance that marks a fundamental turning point in pediatric medicine. The AAP now recommends exome and genome sequencing as a first-tier test for children with global developmental delay or intellectual disability. For over 60,000 pediatricians, this guidance transforms what was once a last-resort diagnostic tool into a frontline standard of care, empowering them to make more informed clinical decisions and dramatically shorten the diagnostic odyssey for millions of children.

The Business of Breakthroughs

While its mission is patient-centric, GeneDx's strategy has also proven to be a financial success story in the highly competitive biotech sector. The company has shown consistent revenue growth, reporting approximately $175.8 million for fiscal year 2024 and continuing its trajectory in 2025. While still operating at a net loss—a common scenario for growth-phase genomics firms—its losses have been steadily narrowing, indicating a clear path toward profitability.

This financial stability allows GeneDx to continue investing heavily in research and technology, further strengthening its competitive advantage. In a market with formidable players like Natera and Centogene, GeneDx's Infinity™ dataset remains its core differentiator, providing an ever-expanding foundation for AI-driven discovery and partnerships with biopharma companies seeking to develop targeted therapies.

The convergence of clinical validation, regulatory support, and a sound business model places GeneDx at the forefront of the precision medicine revolution. For advocates and families, this progress represents more than just technological advancement; it signifies hope.

“Katherine is playing a critical role in ensuring that children like my daughter, Mila, are diagnosed earlier and with greater precision,” said Julia Vitarello, CEO of EveryONE Medicines. “This is where it all begins – connecting children, diagnosed as early as birth, to a new pathway for the rapid development of highly precise, individualized medicines. Together with Katherine’s leadership, we will prove that it's possible to find children early enough to stop disease before it ever begins.”